• Jaguar Health published a July 22, 2026 release on compassionate-use access to liquid oral crofelemer for an EU infant with MVID-related intestinal failure.
• Program update flagged a planned FDA NDA filing for MVID in mid-2027.
• ESPGHAN 2026 data cited PS reductions up to 48% in an MVID patient, up to 40% in two SBS-IF patients, with no significant abnormalities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607220900ACCESSWRNAPR_____1194425) on July 22, 2026, and is solely responsible for the information contained therein.